C4 Therapeutics, Inc. (CCCC)

4,6200 0,0000 (0,00%) Börsenschluss: 04:00PM EDT

C4 Therapeutics, Inc.

490 Arsenal Way
Suite120
Watertown, MA 02472
United States
617 231 0700
https://www.c4therapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 145

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director	986,08k	N/A	1971
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board	45k	N/A	1951
Dr. Stewart Fisher Ph.D.	Chief Scientific Officer	674,57k	N/A	1967
Dr. Leonard M. J. Reyno M.D.	Chief Medical Officer	1,04M	N/A	1962
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Ms. Kendra Adams	CFO & Treasurer	N/A	N/A	N/A
Mr. Mark Mossler	Chief Accounting Officer	N/A	N/A	1973
Ms. Jolie M. Siegel J.D.	Chief Legal Officer & Corporate Secretary	610,4k	1,06M	1977
Ms. Kelly A. Schick	Chief People Officer	N/A	N/A	1980
Dr. Isabel Chiu Ph.D.	Senior Vice President of Strategic Alliances & Business Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Corporate Governance

C4 Therapeutics, Inc.s ISS Governance QualityScore, Stand 29. Juni 2024, lautet 7. Die grundlegenden Scores sind Audit: 2, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.